Status:
UNKNOWN
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT
Lead Sponsor:
University of Ioannina
Collaborating Sponsors:
Baxter Healthcare Corporation
Conditions:
End Stage Renal Disease on Dialysis
Eligibility:
All Genders
18-90 years
Brief Summary
The evaluation and assessment of the influence of the different modalities of renal replacement therapy (RRT), including peritoneal dialysis (PD), conventional hemodialysis with high flux dialyzers, h...
Detailed Description
The sustained inflammatory state in CKD is of complex pathogenesis and is believed to be in part attributable to the augmented activation of innate immune system cell subsets. The activation of the in...
Eligibility Criteria
Inclusion
- adult patients between 18 and \<90 years
- CKD G5 (glomerular filtration rate (GFR) \<15 ml/min/1.73m2)
- conventional hemodialysis treatment thrice weekly for at least three months via permanent vascular access
- patients undergoing PD for at least three months.
Exclusion
- presence of infection
- active malignancy
- liver cirrhosis
- inflammatory bowel disease
- active autoimmune disease
- decompensated heart failure (New York Heart Association (NYHA) IV
- occurence of a major cardiovascular event within less that three months
Key Trial Info
Start Date :
November 7 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04286477
Start Date
November 7 2018
End Date
December 31 2022
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Ioannina
Ioannina, Greece, 45110